论文部分内容阅读
[目的]研究新辅助化疗前后乳腺癌ER、PR和EphA2表达的变化及其临床意义。[方法]采用免疫组化SP法检测新辅助化疗前后ER、PR和EphA2在52例乳腺癌的表达情况。[结果]ER、PR和EphA2的表达均与疗效相关。新辅助化疗后EphA2的阳性表达率显著下降(P<0.05),ER、PR的阳性表达率无明显变化(P>0.05)。[结论]新辅助化疗疗效与ER、PR、EphA2表达水平有关。新辅助化疗可显著降低EphA2的阳性表达,而对ER、PR的表达无显著影响。
[Objective] To investigate the changes of ER, PR and EphA2 expression in breast cancer before and after neoadjuvant chemotherapy and their clinical significance. [Method] The expression of ER, PR and EphA2 in 52 cases of breast cancer before and after neoadjuvant chemotherapy were detected by immunohistochemical SP method. [Results] The expressions of ER, PR and EphA2 were all related to the curative effect. The positive expression rate of EphA2 in neoadjuvant chemotherapy was significantly decreased (P <0.05), while there was no significant change in the expression of ER and PR (P> 0.05). [Conclusion] The effect of neoadjuvant chemotherapy is related to the expression of ER, PR and EphA2. Neoadjuvant chemotherapy can significantly reduce the expression of EphA2, but have no significant effect on the expression of ER and PR.